EraCal Therapeutics
Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-vivo screening platform
Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-vivo screening platform
EraCal Therapeutics is a biotech startup founded in 2017 with a focus on developing first-in-class drugs to treat various diseases. Their mission, as reflected in their slogan "Towards an efficacious and well-tolerated appetite-suppressant using our innovative in-vivo screening platform," indicates their commitment to innovative solutions in the biotechnology, healthcare, and pharmaceutical industries. The company's roots can be traced back to the University of Zurich and Harvard University, showcasing a strong academic foundation. Headquartered in Switzerland, EraCal Therapeutics secured a Seed Round investment on 18th October 2019, with notable participation from Redalpine, Bernina BioInvest, and Life Sciences Fund. With a strong line-up of investors and a promising approach, EraCal Therapeutics is poised to make significant strides in the biotech industry.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Seed Round | Unknown | 3 |
|
18 Oct 2019 |
| Seed Round | Fr.1.00M | 1 | Life Sciences Fund | 04 Jun 2019 |
| Pre Seed Round | Fr.100.00K | 1 |
|
16 Jan 2019 |
| Grant | Fr.20.00K | 1 |
|
13 Jun 2018 |
| Grant | Fr.10.00K | 1 |
|
20 Mar 2018 |
No recent news or press coverage available for EraCal Therapeutics .
We care about your data, and we'd love to use cookies make your experience better.
